These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32920625)

  • 1. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
    Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).
    Walter S; Clanton TB; Langford OG; Rafii MS; Shaffer EJ; Grill JD; Jimenez-Maggiora GA; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):219-225. PubMed ID: 32920623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.
    Walter S; Langford O; Jimenez-Maggiora GA; Abdel-Latif S; Rissman RA; Grill JD; Karlawish J; Atri A; Bruschi S; Hussen K; Donohue MC; Marshall GA; Jicha G; Racke M; Turner RS; van Dyck CH; Venkatesh V; Yarasheski KE; Sperling R; Cummings J; Aisen PS; Raman R
    J Prev Alzheimers Dis; 2024; 11(5):1435-1444. PubMed ID: 39350391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.
    Aisen PS; Sperling RA; Cummings J; Donohue MC; Langford O; Jimenez-Maggiora GA; Rissman RA; Rafii MS; Walter S; Clanton T; Raman R
    J Prev Alzheimers Dis; 2020; 7(4):208-212. PubMed ID: 32920621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.
    Jimenez-Maggiora GA; Bruschi S; Raman R; Langford O; Donohue M; Rafii MS; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):226-233. PubMed ID: 32920624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
    Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
    J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Rafii MS; Sperling RA; Donohue MC; Zhou J; Roberts C; Irizarry MC; Dhadda S; Sethuraman G; Kramer LD; Swanson CJ; Li D; Krause S; Rissman RA; Walter S; Raman R; Johnson KA; Aisen PS
    Alzheimers Dement; 2023 Apr; 19(4):1227-1233. PubMed ID: 35971310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study.
    Sato K; Ihara R; Suzuki K; Niimi Y; Toda T; Jimenez-Maggiora G; Langford O; Donohue MC; Raman R; Aisen PS; Sperling RA; Iwata A; Iwatsubo T
    Alzheimers Dement (N Y); 2021; 7(1):e12135. PubMed ID: 33778148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research.
    Porsteinsson AP; Clark ED
    J Prev Alzheimers Dis; 2020; 7(4):206-207. PubMed ID: 32920620
    [No Abstract]   [Full Text] [Related]  

  • 11. The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.
    Ritchie CW; Muniz-Terrera G; Kivipelto M; Solomon A; Tom B; Molinuevo JL
    J Prev Alzheimers Dis; 2020; 7(1):8-13. PubMed ID: 32010920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease.
    Papp KV; Amariglio RE; Mormino EC; Hedden T; Dekhytar M; Johnson KA; Sperling RA; Rentz DM
    Neuropsychologia; 2015 Jul; 73():169-75. PubMed ID: 26002757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.
    Yaari R; Holdridge KC; Mancini M; Rafii MS; Case M; Battioui C; Sims JR; Aisen PS; Sperling RA
    J Prev Alzheimers Dis; 2024; 11(4):857-868. PubMed ID: 39044494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
    Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
    J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease.
    Lucey BP; Wisch J; Boerwinkle AH; Landsness EC; Toedebusch CD; McLeland JS; Butt OH; Hassenstab J; Morris JC; Ances BM; Holtzman DM
    Brain; 2021 Oct; 144(9):2852-2862. PubMed ID: 34668959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults.
    Insel PS; Donohue MC; Sperling R; Hansson O; Mattsson-Carlgren N
    Ann Clin Transl Neurol; 2020 May; 7(5):776-785. PubMed ID: 32315118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring cognitive change in subjects with prodromal Alzheimer's disease.
    Mura T; Proust-Lima C; Jacqmin-Gadda H; Akbaraly TN; Touchon J; Dubois B; Berr C
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):363-70. PubMed ID: 23840054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.